ArticleJournal of autism and developmental disorders2002
Molecular and cytogenetic analyses on Brazilian youths with pervasive developmental disorders.
Article in Journal of autism and developmental disorders, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 34 citations in OpenAlex.
- The Role of MicroRNAs in Cerebellar Development and Autism Spectrum Disorder During Embryogenesis.Molecular neurobiology · 2017Review
- Model-based evaluation of the impact of formulation and food intake on the complex oral absorption of mavoglurant in healthy subjects.Pharmaceutical research · 2015Article
- Identification of expanded alleles of the FMR1 gene among high-risk population in Indonesia by using blood spot screening.Genetic testing and molecular biomarkers · 2012Article
- Brief report: Sensorimotor gating in idiopathic autism and autism associated with fragile X syndrome.Journal of autism and developmental disorders · 2011Article
- Plasma cytokine profiles in Fragile X subjects: is there a role for cytokines in the pathogenesis?Brain, behavior, and immunity · 2010Article
- The genetic overlap of attention deficit hyperactivity disorder and autistic spectrum disorder.The application of clinical genetics · 2009Article
- Autism profiles of males with fragile X syndrome.American journal of mental retardation : AJMR · 2008Article
- Secondary medical diagnosis in fragile X syndrome with and without autism spectrum disorder.American journal of medical genetics. Part A · 2008Article
- Cytogenetic abnormalities and fragile-X syndrome in Autism Spectrum Disorder.BMC medical genetics · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Pervasive Developmental Disorders (PDDs) constitute a group of behavioral and neurobiological impairment conditions whose main features are delayed communicative and cognitive development. Genetic factors are reportedly associated with PDDs and particular genetic abnormalities are frequently found in specific diagnostic subgroups such as the autism spectrum disorders. This study evaluated cytogenetic and molecular parameters in 30 youths with autism or other PDDs. The fragile X syndrome was the most common genetic abnormality detected, presented by 1 patient with autism and 1 patient with PPD not-otherwise specified (PPD-NOS). One girl with PDD-NOS was found to have tetrasomy for the 15q11-q13 region, and one patient with autism exhibited in 2/100 metaphases an inv(7)(p35q36), thus suggesting a mosaicism 46,XX/46,XX,inv(7)(p15q36) or representing a coincidental finding. The high frequency of chromosomopathies support the hypothesis that PDDs may develop as a consequence to chromosomal abnormalities and justify the cytogenetic and molecular assessment in all patients with PDDs for establishment of diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.